Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

MicroRNA-Regulated ON/OFF Switches for Tumor-Specific mRNA Immunotherapy

FY 2024-25

Summary
Non-small cell lung cancer (NSCLC) remains one of the most challenging malignancies to treat due to its immunosuppressive tumor microenvironment (TME) and resistance to conventional therapies. I propose a novel therapeutic approach that integrates Granzyme A (GzmA), a serine protease inducing pyroptosis and immune activation, with microRNA (miRNA)-regulated ON/OFF switches and lipid nanoparticle (LNP) delivery to achieve tumor-specific targeting. By leveraging the differences in miRNA expression between cancerous and healthy tissues, I will design ON-switches activated by tumor-associated miRNAs, such as miR-21-5p, to promote GzmA translation in lung cancer cells, while OFF-switches, within the same construct, suppressed by miRNAs like Let7-b will prevent off-target effects in healthy tissues. My project has three main objectives: first, to demonstrate tumor-specific mRNA expression using miRNA-regulated switches and a mCherry reporter gene in A549 xenograft mouse models; second, to evaluate the cytotoxic and immune-stimulatory effects of GzmA mRNA in vitro by analyzing cell death and immunogenic cell death markers; and third, to assess the therapeutic efficacy and safety of the ON/OFF switch system with GzmA mRNA in vivo by monitoring tumor regression, immune cell infiltration, tumor microenvironment remodeling, and toxicity. This research aims to provide a novel approach to NSCLC therapy, addressing tumor-specific targeting and immune activation challenges. By achieving these goals, I hope to develop a scalable and versatile platform that can be extended to other solid and cold tumors, offering new hope for treating resistant and metastatic cancers.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530364
Name
Chen David X
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
MicroRNA-Regulated ON/OFF Switches for Tumor-Specific mRNA Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Granzyme A; Immunotherapy; Lipid Nanoparticles; Lung Cancer; Microrna; Mrna; Targeted-Delivery
Abstract
Non-small cell lung cancer (NSCLC) remains one of the most challenging malignancies to treat due to its immunosuppressive tumor microenvironment (TME) and resistance to conventional therapies. I propose a novel therapeutic approach that integrates Granzyme A (GzmA), a serine protease inducing pyroptosis and immune activation, with microRNA (miRNA)-regulated ON/OFF switches and lipid nanoparticle (LNP) delivery to achieve tumor-specific targeting. By leveraging the differences in miRNA expression between cancerous and healthy tissues, I will design ON-switches activated by tumor-associated miRNAs, such as miR-21-5p, to promote GzmA translation in lung cancer cells, while OFF-switches, within the same construct, suppressed by miRNAs like Let7-b will prevent off-target effects in healthy tissues. My project has three main objectives: first, to demonstrate tumor-specific mRNA expression using miRNA-regulated switches and a mCherry reporter gene in A549 xenograft mouse models; second, to evaluate the cytotoxic and immune-stimulatory effects of GzmA mRNA in vitro by analyzing cell death and immunogenic cell death markers; and third, to assess the therapeutic efficacy and safety of the ON/OFF switch system with GzmA mRNA in vivo by monitoring tumor regression, immune cell infiltration, tumor microenvironment remodeling, and toxicity. This research aims to provide a novel approach to NSCLC therapy, addressing tumor-specific targeting and immune activation challenges. By achieving these goals, I hope to develop a scalable and versatile platform that can be extended to other solid and cold tumors, offering new hope for treating resistant and metastatic cancers.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, David X
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~